AIMS: The primary objective of this study was to describe the single dose pharmacokinetics of ribavirin in subjects with normal liver function and those with various degrees of stable chronic liver disease. Additionally this study assessed the safety and tolerability of ribavirin in this population. METHODS: Single oral 600 mg doses of ribavirin were administered to healthy male and female volunteers (n = 6) and patients with stable chronic liver disease (n = 17), in a parallel group study. Pharmacokinetic sampling and tolerability assessments were performed up to 168 h post dose. RESULTS: Single oral doses of 600 mg ribavirin were well tolerated by healthy volunteers and patients with varying degrees of hepatic dysfunction. Although mean Cmax increased with the severity of hepatic dysfunction, there was no change in extent of absorption or renal clearance of ribavirin. CONCLUSIONS: There are no pharmacokinetic reasons for initial dose adjustment of ribavirin in patients with hepatic dysfunction.
AIMS: The primary objective of this study was to describe the single dose pharmacokinetics of ribavirin in subjects with normal liver function and those with various degrees of stable chronic liver disease. Additionally this study assessed the safety and tolerability of ribavirin in this population. METHODS: Single oral 600 mg doses of ribavirin were administered to healthy male and female volunteers (n = 6) and patients with stable chronic liver disease (n = 17), in a parallel group study. Pharmacokinetic sampling and tolerability assessments were performed up to 168 h post dose. RESULTS: Single oral doses of 600 mg ribavirin were well tolerated by healthy volunteers and patients with varying degrees of hepatic dysfunction. Although mean Cmax increased with the severity of hepatic dysfunction, there was no change in extent of absorption or renal clearance of ribavirin. CONCLUSIONS: There are no pharmacokinetic reasons for initial dose adjustment of ribavirin in patients with hepatic dysfunction.
Authors: J J Lertora; A B Rege; J T Lacour; N Ferencz; W J George; R B VanDyke; K C Agrawal; N E Hyslop Journal: Clin Pharmacol Ther Date: 1991-10 Impact factor: 6.875
Authors: O L Laskin; J A Longstreth; C C Hart; D Scavuzzo; C M Kalman; J D Connor; R B Roberts Journal: Clin Pharmacol Ther Date: 1987-05 Impact factor: 6.875
Authors: A M Di Bisceglie; H S Conjeevaram; M W Fried; R Sallie; Y Park; C Yurdaydin; M Swain; D E Kleiner; K Mahaney; J H Hoofnagle Journal: Ann Intern Med Date: 1995-12-15 Impact factor: 25.391
Authors: Clara T M M de Kanter; Joost P H Drenth; Joop E Arends; Henk W Reesink; Marc van der Valk; Robert J de Knegt; David M Burger Journal: Clin Pharmacokinet Date: 2014-05 Impact factor: 5.577
Authors: Elise J Smolders; Clara T M M de Kanter; Bart van Hoek; Joop E Arends; Joost P H Drenth; David M Burger Journal: Drug Saf Date: 2016-07 Impact factor: 5.606